Charles S Elmore

Dr. Charles S Elmore

AstraZeneca (Sweden), Södertälje, Sweden
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2012 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
EIEmre M. Isin
Emre M. Isin
Charles S ElmoreCharles S Elmore
Charles S Elmore
GNGöran N. Nilsson
Göran N. Nilsson
RTRichard A. Thompson
Richard A. Thompson
LWLars Weidolf
Lars Weidolf

8 December 2000 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
KKKelem Kassahun
Kelem Kassahun
PPPaul G. Pearson
Paul G. Pearson
WTWei Tang
Wei Tang
IMIan McIntosh
Ian McIntosh
KLKwan Leung
Kwan Leung
TBThomas A. Baillie
Thomas A. Baillie

1 January 2015 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
Charles S ElmoreCharles S Elmore
Charles S Elmore
RBRyan A. Bragg
Ryan A. Bragg
As Medicinal Chemists are responsible for the synthesis and optimization of compounds, they often provide intermediates for use by isotope chemistry. Nevertheless, there is generally an incomplete understanding of the critical factors involved in the labeling of compounds. The remit of an Isotope Chemistry group varies from company to company, but often includes the synthesis of compounds labeled with radioisotopes, especially H-3 and C-14 and occasionally I-125, and stable isotopes, especially H-2, C-13, and N-15. Often the remit will also include the synthesis of drug metabolites. The methods used to prepare radiolabeled compounds by Isotope Chemists have been reviewed relatively recently. However, the organization and utilization of Isotope Chemistry has not been discussed recently and will be reviewed herein.

1 April 2007 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
SVStella H. Vincent
Stella H. Vincent
JRJames R. Reed
James R. Reed
ABArthur J. Bergman
Arthur J. Bergman
Charles S ElmoreCharles S Elmore
Charles S Elmore
BZBing Zhu
Bing Zhu
GHGary A. Herman
Gary A. Herman
The metabolism and excretion of [14C]sitagliptin, an orally active, potent and selective dipeptidyl peptidase 4 inhibitor, were investigated in humans after a single oral dose of 83 mg/193 μCi. Urine, feces, and plasma were collected at regular intervals for up to 7 days. The primary route of excretion of radioactivity was via the kidneys, with a mean value of 87% of the administered dose recovered in urine. Mean fecal excretion was 13% of the administered dose. Parent drug was the major radioactive component in plasma, urine, and feces, with only 16% of the dose excreted as metabolites (13% in urine and 3% in feces), indicating that sitagliptin was eliminated primarily by renal excretion. Approximately 74% of plasma AUC of total radioactivity was accounted for by parent drug. Six metabolites were detected at trace levels, each representing <1 to 7% of the radioactivity in plasma. These metabolites were the N-sulfate and N-carbamoyl glucuronic acid conjugates of parent drug, a mixture of hydroxylated derivatives, an ether glucuronide of a hydroxylated metabolite, and two metabolites formed by oxidative desaturation of the piperazine ring followed by cyclization. These metabolites were detected also in urine, at low levels. Metabolite profiles in feces were similar to those in urine and plasma, except that the glucuronides were not detected in feces. CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8.

15 September 2012 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
ALAnders T. Lindhardt
Anders T. Lindhardt
RSRoger Simonssen
Roger Simonssen
RTRolf H. Taaning
Rolf H. Taaning
TGThomas M. Gøgsig
Thomas M. Gøgsig
GNGöran N. Nilsson
Göran N. Nilsson
TSTroels Skrydstrup
Troels Skrydstrup